1 day chart
Oncorus, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing active viral immunotherapies to transform outcomes for cancer patients. Using its two platforms, the Company is developing a pipeline of intratumorally and intravenously administered product candidates designed to selectively attack and kill tumor cells and deliver transgenes to stimulate multiple arms of the immune system against tumors. Its lead product candidate, ONCR-177, is an intratumorally administered viral immunotherapy based on its oncolytic HSV-1 platform (oHSV Platform), which leverages the Herpes Simplex Virus type 1 (HSV-1). It is also developing a pipeline of product candidates based on its vRNA Immunotherapy Platform. This platform aims to enable repeat intravenous administration of viral immunotherapies in order to treat cancers that are less amenable to intratumoral injection due to safety and feasibility reasons, such as cancers of the lung.
Buy US stocks in Australia with $0 brokerage and trade ONCR today!
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.